Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

69.45 -1.68 (-2.36%)
Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
67 68 Next >
A Look Into AstraZeneca's Debt
Via Benzinga
GSK's Chief Scientist Says R&D Focus More On Infectious Disease, HIV Amid Patent Expiration, Dwindling Sales
GSK Plc's (NYSE: GSK) top scientist, Tony Wood, who took the helm of R&D last August, says the R&D department is now delivering results. Wood said he is de-emphasizing R&D in oncology and that the R&D... 
Via Benzinga
Rise in Biotech Innovations Generating Hope as Pancreatic Cancer Survival Rates Climb
FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 14, 2023 – USA News Group – Optimism is on the rise as the American Cancer Society is reporting that the five-year survival... 
Via FinancialNewsMedia
AstraZenceca's Tagrisso Shows Survival Benefit In Early-Stage Lung Cancer Settings
Via Benzinga
AstraZeneca's Debt Overview
Shares of AstraZeneca Inc. (NASDAQ:AZN) fell by 5.41% in the past three months. Before having a look at the importance of debt, let's look at how much debt AstraZeneca has. 
Via Benzinga
AstraZeneca Plc (AZN) Q4 2022 Earnings Call Transcript
AZN earnings call for the period ending December 31, 2022. 
Via The Motley Fool
2 Top Biotech Stocks to Buy Right Now
These two companies each pay market-beating dividends to shareholders. 
Via The Motley Fool
AstraZeneca's Immunotherapy Imfinzi Shows Improvement In Survival Chances In Lung Cancer Patients
Via Benzinga
TAGRISSO® (osimertinib) demonstrated strong overall survival benefit in the ADAURA Phase III trial for adjuvant treatment of patients with early-stage EGFR-mutated lung cancer
From AstraZeneca
Via Business Wire
IMFINZI significantly improved event-free survival in AEGEAN Phase III trial for patients with resectable non-small cell lung cancer
From AstraZeneca
Via Business Wire
Sanofi, AstraZeneca Tee Up A Rival To Pfizer In The Multibillion-Dollar RSV Race
These companies aren't working on a vaccine, but a monoclonal antibody. 
Via Investor's Business Daily
AstraZeneca Stock Jumps As Upbeat Guidance Offsets Mixed Quarterly Report
The company's guidance palliated concerns of high expenses this year, an analyst said. 
Via Investor's Business Daily
Schrodinger is an AI-Powered Drug Discovery Developer to Watch
Drug discovery software developer Schrodinger Inc. (NASDAQ: SDGR) stock has been trying to recover after plummeting over 80% off its all-time high of $117 
Via MarketBeat
Topics Artificial Intelligence
3 No-Brainer Stocks to Buy With $400 Right Now
A reasonably small amount of money can go a long way when it's invested in innovative businesses. 
Via The Motley Fool
AstraZeneca-Daiichi Sankyo's Flagship Cancer Drug Shows Meaningful, Durable Responses In Other Solid Tumor Setting
Via Benzinga
4 AI Stocks That Are Revolutionizing Healthcare
With the growing use of AI in healthcare, it has led to a number of stocks that are focused on this industry. 
Via InvestorPlace
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Showed Clinically Meaningful and Durable Responses Across Multiple HER2-expressing Tumor Types In DESTINY-PanTumor02 Phase II Trial
From AstraZeneca
Via Business Wire
Alexion advances commitment to transform patient outcomes in rare neurological diseases at AAN 2023
From AstraZeneca
Via Business Wire
Valneva Shares Updated Data From Now Shelved COVID-19 Vaccine Development Program
Via Benzinga
Why Emergent BioSolutions Stock Tumbled by Almost 12% Today
It's not a good day for investors when their company reports a shocking plunge into the red. 
Via The Motley Fool
Why Compugen Shares Are Up Today
The company released its fourth-quarter and full-year results after the bell Monday. 
Via The Motley Fool
Week In Review: Keymed/Lepu Sign $1.2 Billion Deal Out-Licensing Claudin 18.2 ADC To AstraZeneca
Keymed Bio and Lepu Biopharma out-licensed global rights for their antibody drug conjugate to AstraZeneca in a deal that includes $63 million upfront. Meanwhile, the $937 million agreement between... 
Via Talk Markets
Analysts Holding As Pfizer Waits On Two Phase 3 Studies
Pfizer has two products with great potential, waiting on phase-3 study results. The resulting revenue increase should also improve share value. 
Via MarketBeat
Topics Bankruptcy
Global Market for Acute Myeloid Leukemia Expected to Reach $3.2 Billion By 2029
EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:AZN),(NYSE:BMY),(NYSE:AMAM),(NYSE:GSK) EQNX::TICKER_END 
Via FinancialNewsMedia
Johnson & Johnson: Taking The Bull By The Horns?
Johnson & Johnson is rushing toward a patent cliff but a new shelf offering registration suggests itis gearing up for acquisitions. 
Via MarketBeat
Topics Intellectual Property Regulatory Compliance
Seattle Genetics' 'Refreshing' Enthusiasm Drives Stock Surge; Alkermes Briefly Breaks Out
Seattle Genetics' guidance deliberately excludes a looming opportunity for Padcev. 
Via Investor's Business Daily
AstraZeneca and Merck present final results of key secondary overall survival endpoint from Phase III PROpel trial at ASCO GU Cancers Symposium
From AstraZeneca
Via Business Wire
There's a Lot to Love About Mineralys' Valentine's Day IPO
MLYS added 20% more shares to IPO funding, which goes live on 2/14. The bump secured liquidity to stabilize development, improving market cap to $683 million 
Via MarketBeat
Topics Initial Public Offering
AstraZeneca Forecasts Growth In 2023 Earnings, Revenue Despite Fall In COVID-19 Products, Plans To Deliver 15 New Medicines This Decade
Via Benzinga
AstraZeneca Q4 Earnings Beat, Sales Hurt By COVID Jab
Core earnings of $1.38 per share declined 17% year over year on a reported basis and 5% at constant exchange rates (CER). 
Via Talk Markets
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
67 68 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.